Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the closure of its register of members for the upcoming 2024 Annual General Meeting (AGM) scheduled for June 20, 2025. This closure will occur from June 17 to June 20, 2025, during which no share transfers will be registered. Shareholders listed on the register by June 20, 2025, will be eligible to attend and vote at the AGM, emphasizing the importance for unregistered shareholders to complete necessary documentation by June 16, 2025. This announcement is crucial for shareholders to ensure their participation in the AGM, impacting their engagement and voting rights in the company’s future decisions.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China. It operates in the biotechnology industry, focusing on the development and production of biopharmaceutical products.
Average Trading Volume: 713,088
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.86B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.